| Value | ₹4.18 Cr |
|---|
BSE filing, NSE: ZYDUSLIFE. Summary written from the filing by ALFA Finder's alert engine.
Zydus Lifesciences Ltd: key numbers
- Share price
- ₹1,184.40
- Market cap
- ₹1,19,178 Cr
- Revenue (annual)
- ₹27,148 Cr
- Net profit (annual)
- ₹5,040 Cr
- P/E (TTM)
- 26.4×Sector 48.7×
- Promoter holding
- 75.01%+0.00% QoQ
- FII holding
- 7.05%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zydus Lifesciences Ltd
All →Zydus Lifesciences Partnership
Zydus Lifesciences' division Zylidac Bio partnered with Prolific Machines to scale their next-generation biologics manufacturing platform for GMP production.
Zydus Lifesciences Regulatory Approval
Zydus Lifesciences received USFDA approval for its Estradiol-Levonorgestrel Transdermal System ANDA, designated as a CGT. The product is eligible for 180-day exclusivity upon first commercial marketing.
Zydus Lifesciences Board Meeting Date
Zydus Lifesciences intimated a board meeting on 4 Nov 2026 to approve unaudited Q1/H1 FY27 results. Trading window remains closed until 6 Nov 2026.
Zydus Lifesciences Other Announcement
Zydus Lifesciences Limited has been assigned an ESG rating of 71 by NSRAL for the financial year 2026. This unsolicited rating reflects the company's sustainability performance.
Zydus Lifesciences Capacity Expansion: ₹190 Cr Investment
Zydus' JV with Sunshine Healthcare signed a BOI agreement to establish a pharma plant in Sri Lanka. Investment exceeds USD 20 million (~₹190 Cr), targeting 2028.
- Value
- ₹190.0 Cr
Zydus Lifesciences Business Update
Zydus Lifesciences presented post-hoc analysis from its EPICS-III clinical trial for Saroglitazar at ACG 2026. The drug remains under regulatory review for PBC treatment.
Other legal & regulatory announcements
All →Waaree Energies Legal & Regulatory
Waaree Energies disclosed GPCB's January 2026 closure direction for its Degam solar cell plant, since revoked and extended. Interim compensation and bank guarantees total ₹0.17 Crore.
- Value
- ₹0.17 Cr
5Paisa Capital Legal & Regulatory
5paisa Capital Ltd received a favourable income tax order for AY 2023-24, granting relief of ₹40.03 crore against a total disputed amount of ₹42.90 crore.
- Value
- ₹40.03 Cr
5Paisa Capital Legal & Regulatory
5paisa Capital's appeal against an Income Tax order for A.Y. 2023-24 was partly allowed, granting the company relief of ₹40.03 Crore.
- Value
- ₹42.90 Cr
Max Healthcare Institute Legal & Regulatory
Max Healthcare informed the Exchange that the NCLT hearing regarding petitions against its subsidiary, Kalinga Hospital Ltd., was adjourned to October 30, 2026.
Bank of Baroda Legal & Regulatory
Bank of Baroda clarified media-reported interim applications filed by Dr. BR Shetty in the Bombay High Court. The bank says it has not been served and calls the allegations untested.
Canara Bank Legal & Regulatory
Canara Bank disclosed an RBI penalty of Rs. 7,30,000 over ATM cashout at 73 ATMs in Karnataka and Tamil Nadu. The penalty is the only quantified impact.
- Value
- ₹0.07 Cr